文献速递慢性肾脏病

糖尿病肾病的分子机制与治疗靶点

Molecular mechanisms and therapeutic targets for diabetic kidney disease.
PubMed 文献 · Kidney Int · 2022-06-03

本文综述糖尿病肾病发病与进展的分子驱动因素,聚焦炎症与纤维化介质等目前较少作为主要治疗靶点的因素。近期临床试验结果提示有前景的新药疗法及饮食策略可用于治疗糖尿病肾病。

要点

  • 糖尿病肾病全球疾病负担高,显著增加肾衰竭和心血管事件风险。
  • 现有治疗下仍存在显著的疾病进展残余风险,亟需新疗法。
  • 炎症与纤维化介质是 largely 未作为主要治疗靶点的分子驱动因素。

核心结论

  • 糖尿病肾病由糖代谢紊乱启动,触发代谢、血流动力学、炎症和纤维化过程促进疾病进展。
  • 炎症和纤维化介质在糖尿病肾病病理生理中起关键作用,且 largely 未作为主要治疗靶点。
  • 近期临床试验结果提示有前景的新药疗法及饮食策略可用于治疗糖尿病肾病。

研究设计与样本

  • 综述总结糖尿病肾病发病与进展的分子驱动因素现有证据。

主要发现

  • 糖尿病肾病由糖尿病相关糖代谢紊乱启动,进而触发代谢、血流动力学、炎症和纤维化过程。
  • 炎症和纤维化介质在糖尿病肾病病理生理中有关键作用,且 largely 未作为主要治疗靶点。
  • 近期临床试验结果提示有前景的新药疗法及饮食策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetic kidney disease has a high global disease burden and substantially increases the risk of kidney failure and cardiovascular events. Despite treatment, there is substantial residual risk of disease progression with existing therapies. Therefore, there is an urgent need to better understand the molecular mechanisms driving diabetic kidney disease to help identify new therapies that slow progression and reduce associated risks. Diabetic kidney disease is initiated by diabetes-related disturbances in glucose metabolism, which then trigger other metabolic, hemodynamic, inflammatory, and fibrotic processes that contribute to disease progression. This review summarizes existing evidence on the molecular drivers of diabetic kidney disease onset and progression, focusing on inflammatory and fibrotic mediators-factors that are largely unaddressed as primary treatment targets and for which there is increasing evidence supporting key roles in the pathophysiology of diabetic kidney disease. Results from recent clinical trials highlight promising new drug therapies, as well as a role for dietary strategies, in treating diabetic kidney disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Tuttle KR, Agarwal R, Alpers CE, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022. PMID: 35661785. doi:10.1016/j.kint.2022.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。